Trending NewsTrending NewsNASDAQ:IMA ImageneBio (IMA) Stock Price, News & Analysis $3.12 -0.08 (-2.34%) As of 10:54 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About ImageneBio Stock (NASDAQ:IMA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ImageneBio alerts:Sign Up Key Stats Today's Range$3.00▼$3.2050-Day Range$3.20▼$5.0852-Week Range$3.00▼$7.89Volume14,791 shsAverage Volume113,032 shsMarket Capitalization$35.47 millionP/E RatioN/ADividend YieldN/APrice Target$28.00Consensus RatingHold Company Overview ImageneBio, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for immune-mediated and inflammatory diseases. Its research and development pipeline includes investigational medicines at various stages of clinical development; the company does not yet have marketed products. Key programs include IMG-007, an investigational antibody targeting OX40 being studied for atopic dermatitis and other inflammatory conditions, and IMG-004, an oral investigational BTK inhibitor for immune-mediated diseases. These candidates remain in development and have not been approved for commercial use. ImageneBio was formed through the combination of I-Mab and Inmagene Biopharmaceuticals, bringing together drug-development programs and expertise in biotechnology. Its work is centered on advancing clinical research, with potential uses for its therapies to be assessed through ongoing studies.AI Generated. May Contain Errors. Read More ImageneBio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreIMA MarketRank™: 2.975905218315 of 5 starsImageneBio scored higher than 60% of companies evaluated by MarketBeat, and ranked 434th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingImageneBio has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 strong buy rating, no buy ratings, no hold ratings, and 2 sell ratings.Upside PotentialImageneBio has a consensus price target of $28.00, representing about 775.0% upside from its current price of $3.20.Amount of Analyst CoverageImageneBio has only been the subject of 2 research reports in the past 90 days.Read more about ImageneBio's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for ImageneBio are expected to grow in the coming year, from ($3.47) to ($3.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ImageneBio is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ImageneBio is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImageneBio has a P/B Ratio of 0.28. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.41% of the float of ImageneBio has been sold short.Short Interest Ratio / Days to CoverImageneBio has a short interest ratio ("days to cover") of 3.96, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ImageneBio has recently decreased by 25.09%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImageneBio does not currently pay a dividend.Dividend GrowthImageneBio does not have a long track record of dividend growth. News and Social Media1.1 / 5News Sentiment-0.30 News SentimentImageneBio has a news sentiment score of -0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 12 news articles for ImageneBio this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for IMA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ImageneBio insiders have not sold or bought any company stock.Percentage Held by Insiders2.22% of the stock of ImageneBio is held by insiders.Percentage Held by Institutions75.00% of the stock of ImageneBio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ImageneBio's insider trading history. Receive IMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ImageneBio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IMA Stock News HeadlinesImageneBio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 10, 2026 | marketscreener.comMImageneBio Reports Third Quarter 2026 Financial ResultsNovember 9, 2026 | globenewswire.comYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.November 17 at 1:00 AM | Profits Run (Ad)ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 2, 2026 | globenewswire.comImageneBio Corporate Event Calendar | NASDAQ:IMASeptember 13, 2026 | benzinga.comImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New YorkSeptember 8, 2026 | markets.businessinsider.comImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New YorkSeptember 8, 2026 | globenewswire.comImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 17, 2026 | markets.businessinsider.comSee More Headlines IMA Stock Analysis - Frequently Asked Questions How have IMA shares performed this year? ImageneBio's stock was trading at $6.90 on January 1st, 2026. Since then, IMA stock has decreased by 53.6% and is now trading at $3.20. How were ImageneBio's earnings last quarter? ImageneBio, Inc. (NASDAQ:IMA) announced its quarterly earnings data on Monday, November, 9th. The company reported ($0.91) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by $0.08. When did ImageneBio's stock split? ImageneBio's stock reverse split before market open on Monday, July 28th 2025.The 1-12 reverse split was announced on Friday, July 25th 2025. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 25th 2025. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. Who are ImageneBio's major shareholders? Top institutional investors of ImageneBio include Blue Owl Capital Holdings LP (10.00%) and Goldman Sachs Group Inc. (0.10%). Insiders that own company stock include Otello Stampacchia, David P Bonita and Joseph P Slattery. View institutional ownership trends. How do I buy shares of ImageneBio? Shares of IMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ImageneBio own? Based on aggregate information from My MarketBeat watchlists, some other companies that ImageneBio investors own include NVIDIA (NVDA), Rain Enhancement Technologies Holdco (RAIN), Alphabet (GOOG), Immunic (IMUX), Lucid Group (LCID), Micron Technology (MU) and Nebius Group (NBIS). Company Calendar Last Earnings11/09/2026Today11/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (36m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 IMA's financial health is in the Red zone, according to TradeSmith. IMA has been in this zone for over 36 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:IMA Previous SymbolNASDAQ:IMA CIK1835579 Webwww.imagenebio.com Phone(857) 343-8292FaxN/AEmployees18Year Founded2016Price Target and Rating Average Price Target for ImageneBio$28.00 High Price Target$28.00 Low Price Target$28.00 Potential Upside/Downside+795.7%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($4.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$45.35 million Net MarginsN/A Pretax MarginN/A Return on Equity-32.90% Return on Assets-29.66% Debt Debt-to-Equity RatioN/A Current Ratio16.17 Quick Ratio21.47 Sales & Book Value Annual Sales$800 thousand Price / Sales44.35 Cash FlowN/A Price / Cash FlowN/A Book Value$11.29 per share Price / Book0.28Miscellaneous Outstanding Shares11,350,000Free Float12,179,000Market Cap$35.48 million OptionableNot Optionable Beta0.83 Social Links 7 Energy Stocks to Buy and Hold ForeverOil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.Get This Free Report This page (NASDAQ:IMA) was last updated on 11/17/2026 by MarketBeat.com Staff. From Our PartnersA $247 tool for $7Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full ...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredThe $40 trillion number nobody won on Tuesday will touchDemocrats took the House and Senate on election night, but the $40 trillion national debt and the $1 trillion ...Vault Metal | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImageneBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImageneBio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.